ProteinQure is a computational company specializing in the design of groundbreaking peptides with therapeutic applications. With their integrated platform, ProteinStudio, they have developed proprietary technologies and core capabilities to address complex drug design challenges. Leveraging machine learning and simulations, ProteinQure's computational platform enables the design of novel exotic peptides with small amounts of data, resulting in unprecedented drug-like properties.

Their services include tissue-specific delivery peptides, which can deliver therapeutic payloads directly to specific cells via receptor-mediated endocytosis. They also offer the design of synthetic peptide libraries with high-stability scaffolds and enhanced drug-like properties, enabling lead optimization even with limited datasets. Additionally, their platform allows for the modification of natural or synthetic peptide ligands to obtain desirable drug-like properties, such as efficacy, selectivity, solubility, and stability.

ProteinQure's computational protein drug design approach overcomes the challenges associated with designing protein-based therapeutics by leveraging physics-based methods and novel machine learning algorithms. Peptides offer advantages in drug delivery, including tissue specificity and penetration, re-dosability, tolerability, and flexible building blocks. Located in downtown Toronto, ProteinQure benefits from strong relationships with the surrounding players in AI and biotech.

Their mission is to design a healthier future through innovative peptide design. To learn more about ProteinQure and their services, visit their official website at www. proteinqure.

com